Acrux Limited (AU:ACR) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Acrux Limited has announced the U.S. FDA approval of its Nitroglycerin Ointment, alongside securing $2.65 million through a share placement to institutional investors. This development, coupled with a share purchase plan for eligible shareholders, highlights Acrux’s strategic efforts in expanding its footprint in the pharmaceutical market.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
